| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.
|
Eur Heart J
|
2007
|
3.32
|
|
2
|
Factors predisposing to coma and delirium: fentanyl and midazolam exposure; CYP3A5, ABCB1, and ABCG2 genetic polymorphisms; and inflammatory factors.
|
Crit Care Med
|
2013
|
2.31
|
|
3
|
The pharmacokinetics of ezetimibe.
|
Can J Clin Pharmacol
|
2003
|
1.51
|
|
4
|
The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart.
|
Pharmacol Rev
|
2006
|
1.16
|
|
5
|
How critical is the duration of the sampling scheme for the determination of half-life, characterization of exposure and assessment of bioequivalence?
|
J Pharm Pharm Sci
|
2011
|
1.14
|
|
6
|
The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.
|
Pharmacol Rev
|
2012
|
1.10
|
|
7
|
The impact of a multidisciplinary information technology-supported program on blood pressure control in primary care.
|
Circ Cardiovasc Qual Outcomes
|
2009
|
0.99
|
|
8
|
Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.
|
Ann Pharmacother
|
2013
|
0.93
|
|
9
|
An evaluation of pharmacists' expectations towards pharmacogenomics.
|
Pharmacogenomics
|
2013
|
0.90
|
|
10
|
Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.
|
J Cardiovasc Pharmacol
|
2003
|
0.90
|
|
11
|
Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure.
|
Br J Clin Pharmacol
|
2008
|
0.89
|
|
12
|
Validation of warfarin pharmacogenetic algorithms in clinical practice.
|
Pharmacogenomics
|
2012
|
0.88
|
|
13
|
Drug-induced long QT syndrome in women: review of current evidence and remaining gaps.
|
Gend Med
|
2008
|
0.86
|
|
14
|
The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
|
Br J Clin Pharmacol
|
2006
|
0.84
|
|
15
|
Genetic determinants of response to aspirin: appraisal of 4 candidate genes.
|
Thromb Res
|
2011
|
0.84
|
|
16
|
Lengthening of cardiac repolarization in isolated guinea pigs hearts by sequential or concomitant administration of two IKr blockers.
|
J Pharm Sci
|
2010
|
0.84
|
|
17
|
Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors.
|
J Heart Lung Transplant
|
2010
|
0.83
|
|
18
|
Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.
|
J Popul Ther Clin Pharmacol
|
2013
|
0.82
|
|
19
|
Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination.
|
Theor Biol Med Model
|
2009
|
0.81
|
|
20
|
QRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profile.
|
Fundam Clin Pharmacol
|
2011
|
0.81
|
|
21
|
Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.
|
Antimicrob Agents Chemother
|
2008
|
0.81
|
|
22
|
Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software.
|
Am J Geriatr Pharmacother
|
2011
|
0.81
|
|
23
|
Drug-induced long QT syndrome and torsade de pointes.
|
Can J Cardiol
|
2005
|
0.81
|
|
24
|
Gender-related differences in drug-induced prolongation of cardiac repolarization in prepubertal guinea pigs.
|
J Cardiovasc Pharmacol Ther
|
2009
|
0.80
|
|
25
|
Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism.
|
PLoS One
|
2010
|
0.80
|
|
26
|
Domperidone and sudden cardiac death: How much longer should we wait?
|
J Cardiovasc Pharmacol
|
2013
|
0.80
|
|
27
|
Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.
|
J Psychopharmacol
|
2006
|
0.80
|
|
28
|
Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
|
Antimicrob Agents Chemother
|
2008
|
0.80
|
|
29
|
Week-long high-maintenance dose clopidogrel regimen achieves better platelet aggregation inhibition than a standard loading dose before percutaneous coronary intervention: results of a double-blind, randomized clinical trial.
|
J Interv Cardiol
|
2009
|
0.79
|
|
30
|
Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin.
|
Int J Cardiol
|
2009
|
0.79
|
|
31
|
Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan.
|
Ann Pharmacother
|
2008
|
0.79
|
|
32
|
Impact of glucose concentration on cardiac ventricular repolarization under I Kr/I Ks blocking agents.
|
J Mol Cell Cardiol
|
2009
|
0.79
|
|
33
|
Increased risk of myocardial infarction associated with angiotensin-converting enzyme gene polymorphism is age dependent.
|
J Clin Pharmacol
|
2010
|
0.78
|
|
34
|
Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.
|
Pharmacogenetics
|
2003
|
0.78
|
|
35
|
Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5 and inhibition by ketoconazole.
|
Drug Metab Lett
|
2010
|
0.78
|
|
36
|
Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy.
|
Ther Drug Monit
|
2015
|
0.77
|
|
37
|
Rosuvastatin blocks hERG current and prolongs cardiac repolarization.
|
J Pharm Sci
|
2011
|
0.77
|
|
38
|
PRKCB is associated with calcineurin inhibitor-induced renal dysfunction in heart transplant recipients.
|
Pharmacogenet Genomics
|
2012
|
0.75
|
|
39
|
An improved HPLC assay with fluorescence detection for the determination of domperidone and three major metabolites for application to in vitro drug metabolism studies.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2007
|
0.75
|
|
40
|
Enantioselective quantification of carvedilol in human plasma by HPLC in heavily medicated heart failure patients.
|
J Pharm Biomed Anal
|
2010
|
0.75
|
|
41
|
Modulatory role of verapamil treatment on the cardiac electrophysiological effects of cisapride.
|
Can J Physiol Pharmacol
|
2006
|
0.75
|
|
42
|
Effects of ciprofloxacin on the stereoselective disposition of mexiletine in man.
|
Ther Drug Monit
|
2004
|
0.75
|
|
43
|
Evaluation of Limited Sampling Methods for Oral Busulfan Pharmacokinetic Monitoring in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation.
|
Ther Drug Monit
|
2016
|
0.75
|
|
44
|
Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans.
|
Ther Drug Monit
|
2006
|
0.75
|
|
45
|
Performance of different population pharmacokinetic algorithms.
|
Ther Drug Monit
|
2011
|
0.75
|
|
46
|
Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study.
|
J Clin Pharmacol
|
2012
|
0.75
|
|
47
|
Assessment of competitive and mechanism-based inhibition by clarithromycin: use of domperidone as a CYP3A probe-drug substrate and various enzymatic sources including a new cell-based assay with freshly isolated human hepatocytes.
|
Drug Metab Lett
|
2010
|
0.75
|
|
48
|
High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency.
|
Int J Psychiatry Clin Pract
|
2004
|
0.75
|